Basilea Pharmaceutica AG
BPMUF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.12 | 0.01 | -0.03 | 0.03 |
| FCF Yield | 3.97% | 9.51% | 3.21% | -2.00% |
| EV / EBITDA | 21.54 | 10.16 | 58.39 | 153.37 |
| Quality | ||||
| ROIC | 9.07% | 26.03% | 17.13% | -12.34% |
| Gross Margin | 39.86% | 109.86% | 32.21% | 76.90% |
| Cash Conversion Ratio | 1.46 | 0.99 | 0.86 | 0.36 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.04% | 11.80% | 5.34% | 4.59% |
| Free Cash Flow Growth | -58.75% | 215.81% | 311.19% | -138.48% |
| Safety | ||||
| Net Debt / EBITDA | -1.26 | -0.16 | 4.87 | 21.84 |
| Interest Coverage | 17.55 | -15.81 | 1.21 | -1.81 |
| Efficiency | ||||
| Inventory Turnover | 2.76 | -0.41 | 1.65 | 0.64 |
| Cash Conversion Cycle | 66.79 | -100.43 | 67.76 | 144.69 |